PureTech Health (NASDAQ:PRTC – Get Free Report) is projected to issue its H2 2025 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of ($1.94) per share and revenue of $1.90 million for the quarter. Parties can check the company’s upcoming H2 2025 earning summary page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 9:00 AM ET.
PureTech Health Stock Performance
PureTech Health stock opened at $18.05 on Wednesday. The company’s fifty day simple moving average is $16.88 and its 200-day simple moving average is $17.28. PureTech Health has a 12 month low of $14.50 and a 12 month high of $19.92.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of PureTech Health in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, PureTech Health currently has an average rating of “Sell”.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP boosted its position in shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC – Free Report) by 50.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 at the end of the most recent quarter. 0.04% of the stock is owned by hedge funds and other institutional investors.
About PureTech Health
PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.
PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.
Recommended Stories
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
